IPP Bureau
Shilpa Medicare's Unit IV receives Eurasia GMP approval
By IPP Bureau - December 28, 2024
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Fortis Healthcare appoints Leo Puri as Chairman of the Board
By IPP Bureau - December 28, 2024
Puri is an accomplished leader and financial sector veteran with over four decades of experience
New method for detecting H. pylori and its mutations can help dyspeptic patients in resource poor remote settings: PIB
By IPP Bureau - December 28, 2024
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Dr. Sandip Shah appointed as Chairperson of NABL-QCI
By IPP Bureau - December 28, 2024
Alankit to undertake pending e-KYC verification for AB PMJAY in Gujarat
By IPP Bureau - December 28, 2024
Alankit will undertake the verification of pending e-KYC enrollments through the Beneficiary Identification System (BIS) platform provided by the National Health Authority (NHA).
Zota Health Care receives licnese for Zotamet and Telmisartan in Kyrgyzstan
By IPP Bureau - December 28, 2024
Venus Remedies partners with NSDC for workforce development through skill certification
By IPP Bureau - December 27, 2024
Initiative aimed at enhancing workforce skills and competency in line with industry standards so as to create a talented workforce for the Fourth Industrial Revolution
Briefs: Panacea Biotec and Shelter Pharma
By IPP Bureau - December 27, 2024
Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
By IPP Bureau - December 27, 2024
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Thyrocare secures NABL accreditation for its Labs
By IPP Bureau - December 27, 2024
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
By IPP Bureau - December 27, 2024
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
Yatharth Hospital becomes Uttar Pradesh's first JCI-accredited hospital
By IPP Bureau - December 26, 2024
JCI accreditation is recognized globally
Akums signs Rs. 1,760 crore CDMO agreement with a leading global pharma company
By IPP Bureau - December 26, 2024
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
Kwality Pharmaceuticals receives approval for Tamoxifen 20mg Tablet in South Africa
By IPP Bureau - December 26, 2024
This approval is a significant achievement in expanding the availability of this critical therapeutic,
Aarti Drugs receives EIR from USFDA for Tarapur API facility
By IPP Bureau - December 26, 2024
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
